Pertinax Pharma are a medical device company based in Bristol, UK. We make innovative antimicrobial technologies for use in medical devices.
Our patented materials can be incorporated into a wide range of medical device material substrates, including polymers and coatings. The technology works by gradually and steadily releasing chlorhexidine, a well known antiseptic material, thus protecting against infection. A key aspect of our technology offering is that it is antibiotic-free, meaning that it does not contribute to the growth of antibiotic resistance. We see the opportunity to develop anti-infective medical devices that help stem the spread of resistant bacteria as the driving force behind our products.
Dr Michele Barbour, Chief Executive Officer and founder, has overall responsibility for strategic direction of the company. She is the inventor of Pertinax technology and is also a respected academic in the field of biomaterials and has published over 50 peer-reviewed publications.
The company is funded by a combination of equity-based investment and public grant money. If you are or represent an investor and are interested in learning more about investment opportunities, contact us.